John Gatfield

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Discovery of Galactopyranose-1-carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin-3 Inhibitors.

Discovery of Galactopyranose-1-carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin-3 Inhibitors.

Journal: ChemMedChem
Published: December 18, 2024

A uniquely efficacious type of CFTR corrector with complementary mode of action.

A uniquely efficacious type of CFTR corrector with complementary mode of action.

Journal: Science advances
Published: March 01, 2024

Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Journal: Journal of medicinal chemistry
Published: February 08, 2024

Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder.

Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder.

Journal: The International journal of eating disorders
Published: November 01, 2023

Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Journal: RSC medicinal chemistry
Published: October 14, 2023

The metabolism of the dual orexin receptor antagonist daridorexant.

The metabolism of the dual orexin receptor antagonist daridorexant.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: February 22, 2023

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.

Journal: ChemMedChem
Published: July 15, 2020

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.

Journal: ChemMedChem
Published: November 01, 2019

GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

Journal: PloS one
Published: May 10, 2019

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.

Journal: ChemMedChem
Published: April 17, 2019

The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.

The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.

Journal: American journal of respiratory cell and molecular biology
Published: December 12, 2018

Novel high-throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors.

Novel high-throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors.

Journal: PloS one
Published: July 05, 2018
Showing 1-12 of 33

Last Updated: 09/26/2026